Skip to main content
Fig. 1 | Acta Neuropathologica Communications

Fig. 1

From: Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study

Fig. 1

MMP9 plasma level is predictive of bevacizumab efficacy (AVAglio trial). A Patient characteristics in the two arms of AVAglio ancillary sub-population. B Overall Survival (OS, top) and Progression Free Survival (PFS, bottom) according to low plasma level of MMP9 (left) or high plasma level of MMP9 (right) at baseline. RT: radiotherapy; TMZ: temozolomide; BEV: bevacizumab; Plb: placebo

Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us